Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07213973 · ClinicalTrials.gov registry record · Phase 2

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
20
Study locations

NCT07213973 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 40 participants, below the 177-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07213973, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

Conditions Studied

Hidradenitis Suppurativa (HS)

Interventions

  • DRUG Povorcitinib

Study Locations (20)

Florida

  • University of Miami Miller School of Medicine - Miami
  • Skin Research of South Florida, Llc - Miami
  • Trueblue Clinical Research - Tampa

Michigan

  • Oakland Hills Dermatology Pc - Auburn Hills
  • Wayne State University Physician Group Dermatology - Detroit
  • Revival Research Institute, Llc Troy - Troy

Arizona

  • Medical Dermatology Specialists Phoenix - Phoenix
  • Saguaro Dermatology - Phoenix

Alabama

  • University of Alabama At Birmingham - Birmingham

Connecticut

  • Uconn Health - Farmington

Georgia

  • Advanced Medical Research Pc - Sandy Springs

Illinois

  • Endeavor Health Medical Group - Skokie

Kansas

  • Dermatology Skin Cancer Center Leawood - Leawood

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-02-02
Est. Completion 2028-03-25
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07213973

The ClinicalTrials.gov registry entry for NCT07213973 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (77% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which Povorcitinib is the first listed.

NCT07213973 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Michigan, Arizona.

Frequently Asked Questions

What is clinical trial NCT07213973 about?

NCT07213973 is a clinical study titled "Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

What is the current status of trial NCT07213973?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-02-02. Estimated completion is 2028-03-25.

What conditions does trial NCT07213973 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).

What interventions are being tested in trial NCT07213973?

The interventions under investigation include: Povorcitinib (DRUG).

Who is sponsoring clinical trial NCT07213973?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07213973 being conducted?

This trial has 20 study locations across Alabama, Arizona, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa (HS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa (HS)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.